The FDA’s June 2021 approval of Aduhelm (aducanumab), the first plaque-targeting therapy, rattled the company, regulators and the market. BioWorld brought together two experts to get their thoughts as each is involved in developing vaccines or treatments for Alzheimer’s or Parkinson’s disease. Michael Agadjanyan is the president of Nuravax Inc., which is developing antibodies for preventing Alzheimer’s and Parkinson’s disease. We also spoke with Robert Glanzman, who is chief medical officer of Clene Nanomedicine Inc., which is developing a nanotherapeutic for Parkinson’s disease. Both have strong views on Aduhelm. They also had a spirited debate on the science of curing dementia.
The BioWorld Insider Podcasts provides timely and focused one-on-one interviews with the same key sources typically interviewed for articles such as company founders, executives, top researchers and regulators. Topics are prioritized based on the same criteria we use when selecting news to feature in BioWorld, which for more than 30 years reports the breaking news — and provides key perspective — on hundreds of therapeutics and devices in development, the companies behind those candidates, the business development transactions that evolve the markets, and the regulatory hurdles that both challenge and guard the processes.